Financial Performance - The company expects a net loss of approximately ¥327 million for the fiscal year 2025, attributed to various factors including operational challenges [2]. - The estimated net profit attributable to the parent company, excluding non-recurring gains and losses, is projected to be around ¥208 million in loss [4]. - The previous year's net profit attributable to the parent company was a loss of ¥89.63 million, with a total profit of -¥121.54 million [5]. Reasons for Loss - The primary reason for the anticipated loss is the shutdown of the subsidiary Shaanxi Youbang Biopharmaceutical Technology Co., which has led to a bad debt provision impacting the company's performance by approximately ¥125 million [7]. - The subsidiary's asset impairment, based on an evaluation, is expected to affect the net profit by about ¥87 million, contributing to a total impact of approximately ¥114 million on the company's performance [7]. Sales and Operational Challenges - The company's sales revenue has slightly declined due to changes in the pharmaceutical industry policies and macroeconomic conditions, prompting adjustments in sales strategies [7]. - The company is increasing investments in channel and brand development to counteract the decline in sales revenue [7]. - The operational costs remain high due to the simultaneous operation of new and old production bases during the product transition phase [7]. Financial Reporting - The financial data provided is preliminary and subject to change upon the completion of the official audited annual report for 2025 [9]. - The company assures that there are no significant uncertainties affecting the accuracy of this earnings forecast [8].

Core Viewpoint - The company, Shaanxi Kanghui Pharmaceutical Co., Ltd., is providing a guarantee for its subsidiary, Sichuan Chunsheng Pharmaceutical Group Co., Ltd., for a credit facility of 8 million RMB from Sichuan Tianfu Bank, which is aimed at supporting the subsidiary's operational needs [1][2]. Group 1: Guarantee Details - The company will provide a joint liability guarantee for the credit facility, covering the principal amount of 8 million RMB along with interest, penalties, and other related costs, with a guarantee period of three years from the debt maturity date [2][5]. - The subsidiary's shareholder, Mr. Luo Chunming, and Ms. Yin Nianjuan have signed a counter-guarantee agreement, assuming a counter-guarantee responsibility of 3.92 million RMB, which aligns with the company's guarantee period [2][6]. Group 2: Internal Decision-Making Process - The company’s board of directors approved the guarantee for the subsidiary during meetings held on April 27, 2025, and May 20, 2025, allowing for a total guarantee limit of 199 million RMB for the fiscal year 2025, with a specific limit of 34 million RMB for Chunsheng Pharmaceutical [3][9]. Group 3: Necessity and Reasonableness of the Guarantee - The guarantee is deemed necessary and reasonable as it aligns with the operational needs of the subsidiary and is within the approved limits by the shareholders, with the subsidiary currently having a stable operational status and no overdue debts [8][9]. Group 4: Cumulative Guarantee Situation - As of the announcement date, the total guarantee amount provided by the company for its subsidiaries is 87.03 million RMB, which represents 10.48% of the company's latest audited net assets as of the end of 2024 [11]. - If the subsidiary draws the 8 million RMB loan, the total guarantee amount will increase to 97.83 million RMB, accounting for 11.41% of the company's net assets [11].

Core Viewpoint - Kanghui Co., Ltd. announced that as of the disclosure date, its subsidiary, Chunsheng Pharmaceutical, has applied for an 8 million yuan loan from Tianfu Bank, which has not yet been drawn [1] Group 1: Loan and Guarantees - The total amount of guarantees provided by the company for its controlling subsidiaries (including controlling grand-subsidiaries) is 87.0329 million yuan [1] - The guarantees provided by the controlling subsidiary to its wholly-owned subsidiary amount to 2.8 million yuan [1] - The total guarantees provided by the company and its controlling subsidiaries amount to 89.8329 million yuan, which represents 10.48% of the company's latest audited net assets attributable to shareholders as of the end of 2024 [1] Group 2: Future Implications - If Chunsheng Pharmaceutical draws the aforementioned 8 million yuan loan, the total guarantees provided by the company and its controlling subsidiaries will increase to 97.8329 million yuan, representing 11.41% of the company's latest audited net assets attributable to shareholders as of the end of 2024 [1] - The company does not provide guarantees for entities outside of its controlling subsidiaries (including controlling grand-subsidiaries) [1] - There are no overdue guarantees from the company or its controlling subsidiaries (including controlling grand-subsidiaries) [1]

证券代码：603139 证券简称：康惠股份 公告编号：2026-004 陕西康惠制药股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股子公司对外担保总额（万元） | 8,983.29 | | 对外担保总额占上市公司最近一期经审计净资产的比例（%） | 10.48 | 一、担保情况概述 （一） 担保的基本情况 公司拟作为担保方为该授信额度项下流动资金贷款提供连带责任保证，并与 天府银行签订《最高额保证合同》，担保债务本金为 800 万元人民币和相应的利 息、罚息、违约金等，保证期间为主合同约定的债务人履行债务期限届满之日起 三年。同时，春盛药业股东骆春明先生及其一致行动人尹念娟女士与公司签署《反 担保合同》，以连带责任保证的方式在《最高额保证合同》所担保的债权本金的 49%范围内向公司承担反担保责任，即反担保额为人 ...

2026 年第一次临时股东会 会议资料 股票简称：康惠股份 股票代码：603139 康惠股份 2026 年第一次临时股东会会议资料 陕西康惠制药股份有限公司 2026 年 1 月 康惠股份 2026 年第一次临时股东会会议资料 目 录 | 2026 | 年第一次临时股东会会议须知 | | - | 1 - | | --- | --- | --- | --- | --- | | 2026 | 年第一次临时股东会会议议程 | | - | 3 - | | 议案一 | 关于 2025 年度日常关联交易发生情况及 | 2026 年度日常关联交易预计的议案 | - | 4 - | 陕西康惠制药股份有限公司 2026 年第一次临时股东会会议须知 为维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证股东会的顺利进 行，根据《公司法》、《公司章程》及公司《股东会议事规则》等法律法规的有关规定，特制 定本须知，请出席股东会的全体人员遵照执行。 一、本次会议期间，全体出席会议人员应以维护股东合法权益，确保会议正常进行，提 高议事效率为原则，认真履行法定义务。 二、为保证本次会议的严肃性和正常秩序，切实维护股东的合法权益，务 ...

Group 1 - The NMN concept index rose by 1.95%, ranking fourth among concept sectors, with 16 stocks increasing in value, including Meibang Technology which hit a 30% limit up [1] - Notable gainers in the NMN sector included Hongyang Sun, Youa Shares, and Chenguang Biology, which rose by 6.54%, 3.52%, and 3.35% respectively [1] - The sector experienced a net outflow of 51 million yuan in main funds, with six stocks seeing net inflows, led by Zhongsheng Pharmaceutical with a net inflow of 93.86 million yuan [2][3] Group 2 - The main fund inflow ratios were highest for Guoyao Modern, Zhongsheng Pharmaceutical, and Hongyang Sun, with net inflow rates of 6.13%, 4.99%, and 3.77% respectively [3] - The NMN concept fund inflow rankings showed Zhongsheng Pharmaceutical at 1.80% increase with a turnover rate of 11.13%, while Hongyang Sun had a 6.54% increase with a turnover rate of 9.10% [3][4] - Stocks like Yaba Chemical and Anqi Yeast showed negative fund flow, indicating potential concerns in their performance, with Yaba Chemical at -317.96 million yuan and Anqi Yeast at -610.36 million yuan [4]

Group 1 - The company held its sixth board meeting on January 14, 2026, with all nine directors present, and the meeting was deemed legally valid [2][4] - The board approved the proposal regarding the occurrence of related party transactions for 2025 and the expected related party transactions for 2026, which will be submitted for shareholder approval [3][4] - The board also approved the proposal to convene the first extraordinary general meeting of shareholders in 2026, scheduled for January 30, 2026 [5][6] Group 2 - The company and its wholly-owned subsidiary, Beijing Kanghui Zhichuang Technology Co., Ltd., are expected to engage in daily related party transactions based on operational needs, adhering to principles of fairness and reasonableness [10][17] - Independent directors and the audit committee reviewed and approved the related party transaction proposal, confirming that it would not harm the interests of the company or its shareholders [11][12] - The expected related party transactions for 2026 will involve sales of pharmaceutical products and provision of technical services, with pricing based on market standards [16][17] Group 3 - The first extraordinary general meeting of shareholders will utilize a combination of on-site and online voting, with specific details provided for the voting process [20][21] - Shareholders must register for the meeting by January 29, 2026, and can participate either in person or through a proxy [29][32] - The meeting is expected to last half a day, and attendees are responsible for their own expenses [34]

Group 1 - The company announced that its sixth board meeting approved the proposal regarding the occurrence of daily related transactions for the year 2025 and the expected daily related transactions for 2026 [2] - The company also proposed to hold the first extraordinary shareholders' meeting of 2026 [2]

Group 1 - The company, Kanghui Co., Ltd. (603139), announced that it will hold its first extraordinary general meeting of shareholders on January 30, 2026, at 14:30 [1]

Group 1 - The company announced that its sixth board meeting will be held on January 14, 2026, combining in-person and remote participation [1] - The meeting will review the proposal to convene the first extraordinary shareholders' meeting of 2026 [1] Group 2 - Hai Li Biological's valuation has decreased by 50% within eight months despite a ninefold increase in the value of the acquired company [1] - The largest customer of Hai Li Biological is a company that has not yet been established, raising questions about its business model [1]